Sellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish Signal
Sellas Life Sciences has been downgraded to a Strong Sell rating due to concerns about its valuation compared to the potential of its GPS treatment for AML CR2. The company's market capitalization is nearly $1.5 billion, while the risk-adjusted net present value for the treatment is estimated between $259 million and $550 million. Delays in the REGAL Phase 3 trial may indicate issues with the control arm rather than the efficacy of the GPS treatment, increasing the risk of negative outcomes.
- ▪Sellas Life Sciences has been downgraded to Strong Sell due to a disconnect between its valuation and the opportunity for GPS in AML CR2.
- ▪The company's market cap is approaching $1.5 billion, but the risk-adjusted NPV for GPS in AML CR2 is only estimated at $259 to $550 million.
- ▪The delay in the REGAL Phase 3 trial's event accrual may be attributed to improvements in the control arm, raising concerns about the treatment's efficacy.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908050-sellas-life-sciences-regal-delay-may-be-warning-sign-not-bullish-signal"},"author":{"@type":"Person","name":"Stephen Ayers","url":"https://seekingalpha.com/author/stephen-ayers"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
